2024
Placental cytochrome P450 methylomes in infants exposed to prenatal opioids: exploring the effects of neonatal opioid withdrawal syndrome on health horizons
Radhakrishna U, Sadhasivam S, Radhakrishnan R, Forray A, Muvvala S, Metpally R, Patel S, Rawal R, Vishweswaraiah S, Bahado-Singh R, Nath S. Placental cytochrome P450 methylomes in infants exposed to prenatal opioids: exploring the effects of neonatal opioid withdrawal syndrome on health horizons. Frontiers In Genetics 2024, 14: 1292148. PMID: 38264209, PMCID: PMC10805101, DOI: 10.3389/fgene.2023.1292148.Peer-Reviewed Original ResearchNeonatal opioid withdrawal syndromeOpioid withdrawal syndromePlacental tissueWithdrawal syndromeLong-term clinical implicationsPrenatal opioid exposureNOWS treatmentPrenatal opioidsOpioid exposureOpioid effectsOpioid usePharmacologic treatmentCYP genesControl mothersMultiple CYP genesValuable biomarkerClinical implicationsInfantsPersonalized treatmentOpioidsCytochrome P450 enzymesInfinium MethylationEPIC BeadChipTreatmentIllumina Infinium MethylationEPIC BeadChipSyndrome
2023
Long-Term Treatment of Opioid Use Disorder with Medications
Wolfgang A, Weimer M, Na P, Fiellin D, Muvvala S. Long-Term Treatment of Opioid Use Disorder with Medications. 2023, 631-661. DOI: 10.1093/oxfordhb/9780197618431.013.23.ChaptersOpioid use disorderMedical diseasesUse disordersChronic medical diseasesExtended-release naltrexoneLong-term treatmentCause mortalityOUD treatmentClinical outcomesOngoing treatmentOpioid overdoseTerm treatmentMedicationsPsychosocial outcomesAddiction treatmentDisease paradigmOutcomesTreatmentEvidence-based paradigmDiseaseDisordersNegative outcomesImproved retentionRemissionRelapsingFacilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial
Muvvala S, Gan G, Morford K, Dziura J, Esserman D, Porter E, Chan P, Cornman D, Reynolds J, Yager J, Fiellin D, Edelman E. Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial. Journal Of Addiction Medicine 2023, 17: e388-e391. PMID: 37934538, PMCID: PMC10726383, DOI: 10.1097/adm.0000000000001192.Peer-Reviewed Original ResearchConceptsOpioid use disorderAlcohol use disorderTobacco use disorderHIV clinicUse disordersAddiction treatmentSubstance use disorder treatmentUse disorder treatmentMaintenance phaseRandomized trialsStaff preferencesImproved outcomesMultisite Randomized TrialImplementation facilitationDisorder treatmentControl phaseClinicCliniciansTreatment modelTreatmentDisordersSignificant differencesInterventionHigher proportionAddiction treatment models
2022
Integrating Ambulatory Addiction Consultation Service Into a Community Mental Health Center
Jegede O, Muvvala S, Cahill J, Wade R, Jordan A. Integrating Ambulatory Addiction Consultation Service Into a Community Mental Health Center. Journal Of Addiction Medicine 2022, 17: 126-128. PMID: 36111994, DOI: 10.1097/adm.0000000000001081.Peer-Reviewed Original ResearchConceptsCommunity mental health centerAddiction consult serviceMental health centersHealth centersConsult serviceConsultation serviceModel of careEvidence-based treatmentsAcute settingAmbulatory settingAddiction treatmentCareAmbulatory systemDrugsAddiction professionalsTreatmentPatientsReplicable modelSetting
2021
Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation
Edelman EJ, Gan G, Dziura J, Esserman D, Morford KL, Porter E, Chan PA, Cornman DH, Oldfield BJ, Yager JE, Muvvala SB, Fiellin DA. Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2021, 87: 959-970. PMID: 33675619, PMCID: PMC8192340, DOI: 10.1097/qai.0000000000002666.Peer-Reviewed Original ResearchConceptsHIV clinicTreatment medicationsMixed-methods formative evaluationAddiction treatmentTreatment-eligible patientsSubscale scoresAddiction treatment medicationsAdverse health consequencesHIV careMedication complexityTobacco useMedicationsClinicHealth consequencesSite specialistMultidisciplinary teamworkBehavioral servicesTreatment modelOpioidsLocal championsVariable experienceInconsistent availabilityAddiction treatment modelsFocus groupsTreatmentThe effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials
Haeny AM, Gueorguieva R, Montgomery L, Bold KW, Fucito LM, Wu R, Muvvala SB, Zweben A, O'Malley SS. The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials. Addictive Behaviors 2021, 122: 106970. PMID: 34216871, PMCID: PMC9426655, DOI: 10.1016/j.addbeh.2021.106970.Peer-Reviewed Original ResearchConceptsEffects of vareniclineAlcohol use disorderCigarette smokingClinical trialsUse disordersWhite adultsEfficacy of vareniclineNumber of drinksVareniclineSmokingPrimary analysisAlcohol treatmentSecondary analysisAlcohol useTrialsBlack participantsDrinking outcomesLinear mixed modelsAdultsWhite peopleWhite participantsMixed modelingCigarettesDisordersTreatment
2020
Working with HIV clinics to adopt addiction treatment using implementation facilitation (WHAT-IF?): Rationale and design for a hybrid type 3 effectiveness-implementation study
Edelman EJ, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Rebick G, Yager J, Morford K, Muvvala SB, Fiellin DA. Working with HIV clinics to adopt addiction treatment using implementation facilitation (WHAT-IF?): Rationale and design for a hybrid type 3 effectiveness-implementation study. Contemporary Clinical Trials 2020, 98: 106156. PMID: 32976995, PMCID: PMC7511156, DOI: 10.1016/j.cct.2020.106156.Peer-Reviewed Original ResearchConceptsHIV clinicImplementation facilitationAddiction treatmentHealth services research frameworkHybrid type 3Effectiveness-implementation studyEvidence-based counselingSubstantial morbidityClinical outcomesOpioid misusePromoting ActionEffectiveness outcomesClinicFacilitators of integrationType 3Implementation outcomesTreatmentOutcomesWedge designHIVResearch implementationStudy goalFacilitation studiesStaff readinessMedications
2019
Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.
Camenga DR, Colon-Rivera HA, Muvvala SB. Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks. Journal Of Studies On Alcohol And Drugs 2019, 80: 393-402. PMID: 31495374, DOI: 10.15288/jsad.2019.80.393.Peer-Reviewed Original ResearchConceptsTreatment of OUDOpioid use disorderUse disordersClinical benefitTreatment retentionUntreated opioid use disorderHeroin use disorderEvidence-based treatmentsPotential riskLittle published evidenceBuprenorphine treatmentOpioid abstinenceMaintenance treatmentAdolescent patientsTreatment needsMedicationsMethadoneNarrative reviewHealthcare professionalsPublished evidenceBuprenorphineNaltrexoneTreatmentDisordersEfficacy